{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T14:47:02Z","timestamp":1782398822727,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Today"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Rituximab-based desensitization has enabled successful ABO-incompatible (ABO-I) liver transplantation (LT) by preventing antibody-mediated rejection (AMR). However, its effect on T cell-mediated rejection (TCMR) remains unclear. We conducted a comparative analysis between ABO-compatible (ABO-C) and ABO-I LT to evaluate the effects of rituximab-based desensitization on TCMR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 45 LT recipients (32 ABO-C and 13 ABO-I recipients) treated with basiliximab-based immunosuppression. The ABO-I group additionally received rituximab-based desensitization therapy. The lymphocyte subpopulations, rejection, adverse events, and outcomes were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      AMR was not observed in either group. TCMR occurred within 4 weeks post-transplantation in 0% of ABO-C cases and 38.5% of ABO-I cases (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0011). In ABO-C, a significant increase in B cells (CD19+) was observed within the first week, whereas in ABO-I, B cells remained depleted and an increase in T cells (CD3+) was observed. In all the ABO-I cases, TCMR occurred under suppressed CD25\u2009+\u2009conditions. Adverse events were comparable between the groups. The 1-year survival rates for the ABO-C and ABO-I groups were 96.9% and 100%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rituximab-based desensitization in ABO-I LT is associated with an increased incidence of early TCMR. Rituximab-induced B-cell depletion may promote T-cell activation through an IL-2-independent pathway, potentially contributing to increased TCMR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00595-025-03162-3","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T18:35:56Z","timestamp":1767638156000},"page":"1123-1132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of rituximab-based desensitization on T cell-mediated rejection in ABO-incompatible liver transplantation"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3244-2845","authenticated-orcid":false,"given":"Kengo","family":"Sasaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Tokodai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Shono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruhito","family":"Takido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"3162_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/TP.0000000000002147","volume":"102","author":"M Charlton","year":"2018","unstructured":"Charlton M, Levitsky J, Aqel B, O\u2019Grady J, Hemibach J, Rinella M, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients. Transplantation. 2018;102:727\u201343.","journal-title":"Transplantation"},{"key":"3162_CR2","doi-asserted-by":"crossref","unstructured":"Lin NC, Chen CY, Lei HJ, Tsai HL, Tsou YF, Kuo FC et al. A graft-to-recipient weight ratio of less than 0.7% under portal venous hemodynamics monitoring is a risk factor for early graft loss after living donor liver transplantation. Surg Today. 2025.","DOI":"10.1007\/s00595-025-03103-0"},{"key":"3162_CR3","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1007\/s00595-024-02923-w","volume":"55","author":"T Okamoto","year":"2025","unstructured":"Okamoto T, Ogawa E, Okajima H, Masano Y, Okumura S, Yamamoto M, et al. Deceased donor non-composite split liver and intestinal transplantation for children. Surg Today. 2025;55:716\u201322.","journal-title":"Surg Today"},{"key":"3162_CR4","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00595-024-02793-2","volume":"54","author":"T Tomino","year":"2024","unstructured":"Tomino T, Itoh S, Toshima T, Yoshiya S, Nagao Y, Harada N, et al. Venous reconstruction using a round ligament-covered prosthetic vascular graft in right\u2013lobe living\u2013donor liver transplantation: a technical report. Surg Today. 2024;54:795\u2013800.","journal-title":"Surg Today"},{"key":"3162_CR5","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s00595-023-02791-w","volume":"54","author":"T Toshima","year":"2024","unstructured":"Toshima T, Itoh S, Morita K, Nagao Y, Kurihara T, Tomino T, et al. Feasibility of venous cuff using an open round ligament or inferior mesenteric vein around the hepatic vein for a left lobe graft in living-donor liver transplantation. Surg Today. 2024;54:812\u20136.","journal-title":"Surg Today"},{"key":"3162_CR6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00595-024-02918-7","volume":"55","author":"S Yoshiya","year":"2025","unstructured":"Yoshiya S, Itoh S, Toshima T, Bekki Y, Izumi T, Iseda N, et al. The impact of perioperative synbiotics treatment in living-donor liver transplantation after induction of early enteral nutrition. Surg Today. 2025;55:475\u201382.","journal-title":"Surg Today"},{"key":"3162_CR7","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00595-025-03008-y","volume":"55","author":"M Akabane","year":"2025","unstructured":"Akabane M, Imaoka Y, Nakayama T, Esquivel CO, Sasaki K. Effect of sarcopenia on the survival of patients undergoing liver transplantation: a meta-analysis. Surg Today. 2025;55:803\u201313.","journal-title":"Surg Today"},{"key":"3162_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/TP.0000000000004250","volume":"107","author":"H Egawa","year":"2023","unstructured":"Egawa H, Ohdan H, Saito K. Current status of ABO-incompatible liver transplantation. Transplantation. 2023;107:313\u201325.","journal-title":"Transplantation"},{"key":"3162_CR9","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00595-025-03100-3","volume":"55","author":"T Ikegami","year":"2025","unstructured":"Ikegami T, Tsunematsu M, Furukawa K, Onda S, Matsumoto M, Shirai Y, et al. Living donor liver transplantation using ABO-incompatible grafts for chronic and acute liver failure. Surg Today. 2025;55:1347\u201352.","journal-title":"Surg Today"},{"issue":"8","key":"3162_CR10","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1111\/petr.12373","volume":"18","author":"T Shigeta","year":"2014","unstructured":"Shigeta T, Sakamoto S, Uchida H, Sasaki K, Hamano I, Kanazawa H, et al. Basiliximab treatment for steroid-resistant rejection in pediatric patients following liver transplantation for acute liver failure. Pediatr Transplant. 2014;18(8):860\u20137.","journal-title":"Pediatr Transplant"},{"key":"3162_CR11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/lt.20144","volume":"10","author":"CL Liu","year":"2004","unstructured":"Liu CL, Fan ST, Lo CM, Chan SC, Ng IO, Lai CL, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl. 2004;10:728\u201333.","journal-title":"Liver Transpl"},{"key":"3162_CR12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-6143.2008.02493.x","volume":"9","author":"JM Neuberger","year":"2009","unstructured":"Neuberger JM, Mamelok RD, Neuhaus P, Pirenne J, Samuel D, Isoniemi H, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the \u2018ReSpECT\u2019 study. Am J Transplant. 2009;9:327\u201336.","journal-title":"Am J Transplant"},{"key":"3162_CR13","doi-asserted-by":"crossref","unstructured":"Ramirez CB, Doria C, di Francesco F, Iaria M, Kang Y, Marino IR. Basiliximab induction in adult liver transplant recipients with 93% rejection-free patient and graft survival at 24 months. Transplant Proc. 2006;38:3633-5.","DOI":"10.1016\/j.transproceed.2006.10.110"},{"key":"3162_CR14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/jlts.2002.30302","volume":"8","author":"P Neuhaus","year":"2002","unstructured":"Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, et al. Improved treatment response with Basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl. 2002;8:132\u201342.","journal-title":"Liver Transpl"},{"key":"3162_CR15","doi-asserted-by":"publisher","first-page":"541","DOI":"10.5604\/01.3001.0012.2246","volume":"19","author":"M Hashim","year":"2020","unstructured":"Hashim M, Alsebaey A, Ragab A, Soliman HE, Waked I. Efficacy and safety of Basiliximab as initial immunosuppression in liver transplantation: a single center study. Ann Hepatol. 2020;19:541\u20135.","journal-title":"Ann Hepatol"},{"key":"3162_CR16","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/ajt.12520","volume":"14","author":"H Egawa","year":"2014","unstructured":"Egawa H, Teramukai S, Haga H, Tanabe M, Mori A, Ikegami T, et al. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study. Am J Transplant. 2014;14:102\u201314.","journal-title":"Am J Transplant"},{"key":"3162_CR17","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1056\/NEJMc0808481","volume":"360","author":"MR Clatworthy","year":"2009","unstructured":"Clatworthy MR, Watson CJ, Plotnek G, Bardsley V, Chaudhry AN, Bradley JA, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009;360:2683\u20135.","journal-title":"N Engl J Med"},{"key":"3162_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000713","volume":"3","author":"K Tokodai","year":"2017","unstructured":"Tokodai K, Miyagi S, Nakanishi C, Hara Y, Nakanishi W, Goto M, et al. Impact of the trough level of calcineurin inhibitor on the prevalence of donor-specific human leukocyte antigen antibodies during long-term follow-up after pediatric liver transplantation: antibody strength and complement-binding ability. Transplant Direct. 2017;3:e196.","journal-title":"Transplant Direct"},{"key":"3162_CR19","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1111\/ajt.13909","volume":"16","author":"AJ Demetris","year":"2016","unstructured":"Demetris AJ, Bellamy C, Hubscher SG, O\u2019Leary J, Randhawa PS, Feng S, et al. 2016 comprehensive update of the Banff working group on liver allograft pathology: introduction of Antibody-Mediated rejection. Am J Transpl. 2016;16:2816\u201335.","journal-title":"Am J Transpl"},{"key":"3162_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.611795","volume":"12","author":"D Catalan","year":"2021","unstructured":"Catalan D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguillon JC, et al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol. 2021;12:611795.","journal-title":"Front Immunol"},{"key":"3162_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells13040357","author":"J Veh","year":"2024","unstructured":"Veh J, Ludwig C, Schrezenmeier H, Jahrsdorfer B. Regulatory b cells-immunopathological and prognostic potential in humans. Cells. 2024. https:\/\/doi.org\/10.3390\/cells13040357.","journal-title":"Cells"},{"key":"3162_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s40348-023-00174-2","volume":"11","author":"CV Kliem","year":"2024","unstructured":"Kliem CV, Schaub B. The role of regulatory B cells in immune regulation and childhood allergic asthma. Mol Cell Pediatr. 2024;11:1.","journal-title":"Mol Cell Pediatr"},{"key":"3162_CR23","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1002\/ibd.20215","volume":"13","author":"M Goetz","year":"2007","unstructured":"Goetz M, Atreya R, Ghalibafian M, Galle PR, Neurath MF. Exacerbation of ulcerative colitis after rituximab salvage therapy. Inflamm Bowel Dis. 2007;13:1365\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"3162_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000061","volume":"2","author":"JS Perumal","year":"2015","unstructured":"Perumal JS, Kister I, Howard J, Herbert J. Disease exacerbation after rituximab induction in neuromyelitis Optica. Neurol Neuroimmunol Neuroinflamm. 2015;2:e61.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"3162_CR25","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1172\/JCI39933","volume":"120","author":"KA Newell","year":"2010","unstructured":"Newell KA, Asare A, Kirk AD, Gisler TD, Bourcier K, Suthanthiran M, et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120:1836\u201347.","journal-title":"J Clin Invest"},{"key":"3162_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/ki.2010.162","volume":"78","author":"A Pallier","year":"2010","unstructured":"Pallier A, Hillion S, Danger R, Giral M, Racape M, Degauque N, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int. 2010;78:503\u201313.","journal-title":"Kidney Int"},{"key":"3162_CR27","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1172\/JCI39922","volume":"120","author":"P Sagoo","year":"2010","unstructured":"Sagoo P, Perucha E, Sawitzki B, Tomiuk S, Stephens DA, Miqueu P, et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J Clin Invest. 2010;120:1848\u201361.","journal-title":"J Clin Invest"},{"key":"3162_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.2119\/molmed.2011.00281","volume":"18","author":"HM Silva","year":"2012","unstructured":"Silva HM, Takenaka MC, Moraes-Vieira PM, Monteiro SM, Hernandez MO, Chaara W, et al. Preserving the B-cell compartment favors operational tolerance in human renal transplantation. Mol Med. 2012;18:733\u201343.","journal-title":"Mol Med"},{"key":"3162_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1111\/ajt.12508","volume":"14","author":"M Chesneau","year":"2014","unstructured":"Chesneau M, Pallier A, Braza F, Lacombe G, Le Gallou S, Baron D, et al. Unique B cell differentiation profile in tolerant kidney transplant patients. Am J Transplant. 2014;14:144\u201355.","journal-title":"Am J Transplant"},{"key":"3162_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97748-9","volume":"11","author":"A Tanaka","year":"2021","unstructured":"Tanaka A, Ide K, Tanaka Y, Ohira M, Tahara H, Ohdan H. B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4(+) T cell responses in highly sensitized transplant recipients. Sci Rep. 2021;11:18180.","journal-title":"Sci Rep"}],"container-title":["Surgery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-03162-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00595-025-03162-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00595-025-03162-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T13:56:24Z","timestamp":1782395784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00595-025-03162-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3162"],"URL":"https:\/\/doi.org\/10.1007\/s00595-025-03162-3","relation":{},"ISSN":["0941-1291","1436-2813"],"issn-type":[{"value":"0941-1291","type":"print"},{"value":"1436-2813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}